Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

December 1, 2030

Study Completion Date

July 1, 2031

Conditions
Nasopharyngeal Carcinoma (NPC)
Interventions
RADIATION

Reduced-Target Radiotherapy

Experimental group: GTVnx: 69.96 Gy/33 Fr/2.12 Gy; GTVnd: 69.96 Gy/33 Fr/2.12 Gy; CTV1: 60.60 Gy/33 Fr/1.82 Gy; GTV2: No prescription dose (only delineated, actual dose is scattered dose).

RADIATION

Conventional Full-Target Radiotherapy

Control group: GTVnx: 69.96 Gy/33 F/2.12 Gy; GTVnd: 69.96 Gy/33 F/2.12 Gy; CTV1: 59.4 Gy/33 F/1.8 Gy; CTV2: 54 Gy/33 F/1.64 Gy.

Trial Locations (1)

Unknown

RECRUITING

The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000 Recruiting, Zhuhai

All Listed Sponsors
collaborator

Fifth Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Sun Yat-sen University

OTHER

collaborator

Cancer Hospital of Guangxi Medical University

OTHER

collaborator

Fujian Cancer Hospital

OTHER_GOV

collaborator

The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University

UNKNOWN

collaborator

Sun Yat-sen University Cancer Center, Sun Yat-sen University

UNKNOWN

collaborator

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

OTHER

collaborator

Zhejiang Cancer Hospital

OTHER

collaborator

West China Hospital

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

Affiliated Cancer Hospital of Shantou University Medical College

OTHER

collaborator

Yunnan Cancer Hospital

OTHER

collaborator

First Affiliated Hospital of Kunming Medical University

OTHER

collaborator

Wuzhou Red Cross Hospital

OTHER

collaborator

Zhongshan People's Hospital, Guangdong, China

OTHER

collaborator

Southern Medical University, China

OTHER

lead

Ming-Yuan Chen

OTHER

NCT07188584 - Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer | Biotech Hunter | Biotech Hunter